8-KRegulation FD

ABBOTT LABORATORIES 8-K Report, Regulation FD Disclosure (Feb 18, 2022)

Filed February 18, 2022For Securities:ABT

Summary

Abbott Laboratories (ABT) filed an 8-K on February 18, 2022, disclosing a proactive, voluntary recall of Similac-brand powder infant formulas manufactured at its Sturgis, Michigan facility. This recall primarily affects products distributed in the U.S. and Canada. While the company is confirming its previously issued full-year 2022 guidance for adjusted diluted earnings per share from continuing operations at $4.70 or more, it anticipates a one-time expense in the first quarter of 2022 related to recall expenses, including inventory destruction. Despite these recall-related costs, Abbott does not expect the expenses to have a material impact on its consolidated financial statements. The company has issued a press release to inform consumers about the recall. Investors should note that while the company is reiterating its full-year earnings guidance, the undisclosed but expected expenses in Q1 2022 related to this recall warrant attention for short-term financial impacts.

Key Highlights

  • 1Voluntary recall of Similac-brand powder infant formulas manufactured in Sturgis, Michigan, impacting U.S. and Canada.
  • 2Full-year 2022 adjusted diluted EPS guidance reaffirmed at a minimum of $4.70.
  • 3One-time specified item expected in Q1 2022 for recall-related expenses.
  • 4Recall expenses include inventory destruction and other associated costs.
  • 5Abbott does not anticipate a material impact on consolidated financial statements from these recall expenses.
  • 6Company has issued a press release to notify consumers.
  • 7Robert E. Funck, Jr., Executive Vice President, Finance and Chief Financial Officer, signed the report.

Frequently Asked Questions

The 8-K filing is to announce Abbott's proactive, voluntary recall of certain Similac-brand powder infant formulas manufactured at their Sturgis, Michigan facility. This recall mainly affects products distributed in the U.S. and Canada.

Abbott is reaffirming its previously issued full-year 2022 guidance for adjusted diluted earnings per share from continuing operations of at least $4.70. While there will be a one-time expense in Q1 2022 for recall-related costs, the company does not expect these expenses to materially impact its consolidated financial statements or its full-year outlook.

The recall-related expenses mentioned include costs for inventory destruction and other related recall expenses. The exact quantification of these expenses is not yet determined but is expected to be a one-time charge in the first quarter of 2022.

The filing itself does not detail specific safety concerns but states that the recall is a 'proactive, voluntary recall.' The company has issued a press release to inform consumers, which may contain more details on specific product lot numbers or safety information.